CONTEXT: The mitochondrial uncoupling protein-3 (UCP3) has been implicated in the protection of the mitochondrial matrix against lipid-induced mitochondrial damage. Recent evidence points toward mitochondrial aberrations as a major contributor to the development of insulin resistance and diabetes, and UCP3 is reduced in diabetes. OBJECTIVE: We compared skeletal muscle UCP3 protein levels in prediabetic subjects [i.e. impaired glucose tolerance (IGT)], diabetic patients, and healthy controls and examined whether rosiglitazone treatment was able to restore UCP3. PATIENTS, DESIGN, INTERVENTION: Ten middle-aged obese men with type 2 diabetes mellitus [age, 61.4 +/- 3.1 yr; body mass index (BMI), 29.8 +/- 2.9 kg/m(2)], nine IGT subjects (age, 59.0 +/- 6.6 yr; BMI, 29.7 +/- 3.0 kg/m(2)), and 10 age- and BMI-matched healthy controls (age, 57.3 +/- 7.4 yr; BMI, 30.1 +/- 3.9 kg/m(2)) participated in this study. After baseline comparisons, diabetic patients received rosiglitazone (2 x 4 mg/d) for 8 wk. MAIN OUTCOME MEASURES: Muscle biopsies were sampled to determine UCP3 and mitochondrial protein (complex I-V) content. RESULTS: UCP3 protein content was significantly lower in prediabetic IGT subjects and in diabetic patients compared with healthy controls (39.0 +/- 28.5, 47.2 +/- 24.7, and 72.0 +/- 23.7 arbitrary units, respectively; P < 0.05), whereas the levels of the mitochondrial protein complex I-V were similar between groups. Rosiglitazone treatment for 8 wk significantly increased insulin sensitivity and muscle UCP3 content (from 53.2 +/- 29.9 to 66.3 +/- 30.9 arbitrary units; P < 0.05). CONCLUSION: We show that UCP3 protein content is reduced in prediabetic subjects and type 2 diabetic patients. Eight weeks of rosiglitazone treatment restores skeletal muscle UCP3 protein in diabetic patients.
CONTEXT: The mitochondrial uncoupling protein-3 (UCP3) has been implicated in the protection of the mitochondrial matrix against lipid-induced mitochondrial damage. Recent evidence points toward mitochondrial aberrations as a major contributor to the development of insulin resistance and diabetes, and UCP3 is reduced in diabetes. OBJECTIVE: We compared skeletal muscle UCP3 protein levels in prediabetic subjects [i.e. impaired glucose tolerance (IGT)], diabeticpatients, and healthy controls and examined whether rosiglitazone treatment was able to restore UCP3. PATIENTS, DESIGN, INTERVENTION: Ten middle-aged obesemen with type 2 diabetes mellitus [age, 61.4 +/- 3.1 yr; body mass index (BMI), 29.8 +/- 2.9 kg/m(2)], nine IGT subjects (age, 59.0 +/- 6.6 yr; BMI, 29.7 +/- 3.0 kg/m(2)), and 10 age- and BMI-matched healthy controls (age, 57.3 +/- 7.4 yr; BMI, 30.1 +/- 3.9 kg/m(2)) participated in this study. After baseline comparisons, diabeticpatients received rosiglitazone (2 x 4 mg/d) for 8 wk. MAIN OUTCOME MEASURES: Muscle biopsies were sampled to determine UCP3 and mitochondrial protein (complex I-V) content. RESULTS:UCP3 protein content was significantly lower in prediabetic IGT subjects and in diabeticpatients compared with healthy controls (39.0 +/- 28.5, 47.2 +/- 24.7, and 72.0 +/- 23.7 arbitrary units, respectively; P < 0.05), whereas the levels of the mitochondrial protein complex I-V were similar between groups. Rosiglitazone treatment for 8 wk significantly increased insulin sensitivity and muscle UCP3 content (from 53.2 +/- 29.9 to 66.3 +/- 30.9 arbitrary units; P < 0.05). CONCLUSION: We show that UCP3 protein content is reduced in prediabetic subjects and type 2 diabeticpatients. Eight weeks of rosiglitazone treatment restores skeletal muscle UCP3 protein in diabeticpatients.
Authors: Sarah J Lessard; Donato A Rivas; Erin J Stephenson; Ben B Yaspelkis; Lauren G Koch; Steven L Britton; John A Hawley Journal: Am J Physiol Regul Integr Comp Physiol Date: 2010-11-03 Impact factor: 3.619
Authors: Vanesa Viana-Huete; Carlos Guillén; Ana García-Aguilar; Gema García; Silvia Fernández; C R Kahn; Manuel Benito Journal: Endocrinology Date: 2016-02-24 Impact factor: 4.736
Authors: V B Schrauwen-Hinderling; M E Kooi; M K C Hesselink; J A L Jeneson; W H Backes; C J A van Echteld; J M A van Engelshoven; M Mensink; P Schrauwen Journal: Diabetologia Date: 2006-11-09 Impact factor: 10.122
Authors: Ruth C R Meex; Vera B Schrauwen-Hinderling; Esther Moonen-Kornips; Gert Schaart; Marco Mensink; Esther Phielix; Tineke van de Weijer; Jean-Pierre Sels; Patrick Schrauwen; Matthijs K C Hesselink Journal: Diabetes Date: 2009-12-22 Impact factor: 9.461
Authors: Joris Hoeks; Noud A van Herpen; Marco Mensink; Esther Moonen-Kornips; Denis van Beurden; Matthijs K C Hesselink; Patrick Schrauwen Journal: Diabetes Date: 2010-06-23 Impact factor: 9.461
Authors: A Girousse; G Tavernier; C Tiraby; L Lichtenstein; J S Iacovoni; A Mairal; F Villarroya; D Langin Journal: Diabetologia Date: 2009-05-26 Impact factor: 10.122